RecruitMe Clinical Trial

A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb22841 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors (DUET-4)
Study of XmAb22841 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors (DUET-4)
Sponsor:Xencor, Inc.
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAS3476
U.S. Government ID:NCT03849469
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

The primary purpose of this research study is to learn the safety and tolerability of the investigational drug, XmAb 22841 when given alone or in combination with another drug called pembrolizumab.You will be assigned to either receive XmAb22841 alone or in combination with pembrolizumab and you will know what treatment you are receiving. This study will find out if XmAb22841 works in treating tumors like the one that you have and will help researchers identify the side effects that occur from taking XmAb22841 alone and in combination with pembrolizumab. XmAb22841 is an investigational drug that is designed to activate your own cells to kill your tumor. Solid tumors include: bladder cancer, breast cancer, kidney cancer, adrenal cancer, lung cancer, cervical cancer, pancreatic cancer, colon cancer, rectal cancer, liver cancer, and melanoma.

Do You Qualify?
Are you 18 years or older?YesNo
Are you able to perform everyday actions independently?YesNo
Has your cancer progressed after treatment with standard/approved therapies or there are no appropriate available therapies?YesNo
Have you been ever been prescribed PDL-1 therapy as a single agent?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162